longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)

Tip Ranks
Jul 7, 2026 at 10:55 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Bank of America Securities analyst Alec Stranahan reiterated a Sell rating on TG Therapeutics (TGTX) with a $20 price target. This contrasts with the broader market consensus, which suggests a Moderate Buy rating and an average price target of $53.17 for the healthcare stock.

Bank of America Securities analyst Alec Stranahan reiterated a Sell rating on TG Therapeutics today and set a price target of $20.00.

4th of July Sale - 70% Off

  • Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
  • Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Stranahan is a 4-star analyst with an average return of 9.5% and a 53.26% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Agios Pharma, and Revolution Medicines.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TG Therapeutics with a $53.17 average price target.

Login to unlock250characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

TG Therap

TG Therap

USTGTX

-2.71%

Bank of America

Bank of America

USBAC

Moderna

Moderna

USMRNA

LongbridgeAI